- NCIt
- C7985
Loading cancer entity…
Loading cancer entity…
Clinical trials
17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01064648 | Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma | active not recruiting | Phase 1 / Phase 2 | 117 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03228537 | Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma | active not recruiting | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 |
| clinicaltrials |
| NCT02399371 | Pembrolizumab in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 65 | University of ChicagoOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07121374 | NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study(NECIM) | recruiting | Phase 1 / Phase 2 | 37 | University Hospital, AntwerpOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04034238 | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02672033 | Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma | terminated | N/A | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT00365053 | PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2018 | clinicaltrials |
| NCT00243074 | S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01861301 | Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00309946 | Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2014 | clinicaltrials |
| NCT00027703 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2014 | clinicaltrials |
| NCT01105390 | AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 2, 2013 | clinicaltrials |
| NCT00107432 | Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00039182 | Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00025207 | Gefitinib in Treating Patients With Malignant Mesothelioma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00585845 | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment | terminated | Phase 1 | 17 | Anza Therapeutics, Inc.INDUSTRY | 2 | Feb 20, 2009 | clinicaltrials |
Data updated 20 days agoSource updated Sep 9, 2026source: clinicaltrials